title: Effect of troxerutin on laser-induced thrombus formation in rat mesenteric vessels, coagulation parameters and platelet function.
abstract: The antithrombotic effect of Troxerutin have been studied in an experimental model of thrombosis in which rat mesenteric vessels (arterioles and venules) 25-30 microns in diameter were injured by well defined argon laser lesions. Furthermore in vitro effect of this agent on coagulation parameters (IIa, Xa inhibition, TT, heptest), and platelet function (platelet adhesion to the siliconised glass and extracellular matrix, platelet spreading) has been investigated 2 h after oral drug administration. Troxerutin at a dose of 10 mg/kg markedly inhibited thrombus formation in venules. Higher dose (50 mg/kg) was needed to obtain the same antithrombotic effect when arterioles were studied. After application of a single dose of Troxerutin (100 mg/kg) antithrombotic effect lasted for 6 h to 7.5 h when venules were studied, and for 4.5 h to 6 h when arterioles were investigated. In in vitro study we did not observe any effect of Troxerutin on coagulation parameters. In concentrations of 100 micrograms/ml in platelet rich plasma Troxerutin significantly inhibited platelet adhesion to the extracellular matrix and siliconised glass as well as platelet spreading. It is likely that this drug possesses antithrombotic effect evaluated by inhibition of platelet function and protection of endothelial cells.
authors.affiliation: Department of Haematology, Medical Academy, Białystok, Poland.
authors.forename: K
authors.initials: K
authors.lastname: Krupiński
authors.forename: J
authors.initials: J
authors.lastname: Giedrojć
authors.forename: M
authors.initials: M
authors.lastname: Bielawiec
mesh_terms: D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D004195:Disease Models, Animal; D005343:Fibrinolytic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006896:Hydroxyethylrutoside / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008641:Mesenteric Vascular Occlusion / Q000097:blood / Q000517:prevention & control*; D010973:Platelet Adhesiveness / Q000187:drug effects*; D010979:Platelet Function Tests; D051381:Rats; D017208:Rats, Wistar; D013927:Thrombosis / Q000097:blood / Q000517:prevention & control*
chemical_list: D005343:Fibrinolytic Agents; D006896:Hydroxyethylrutoside; C005865:troxerutin